Aldoss I et al. Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated results from the Phase 1/2 SYRUS study. ASH 2025;Abstract 3345.
Aldoss I et al. TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv 2025;9(9):2159-72. Abstract
Aldoss I et al. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer 2022;128(3):529-35. Abstract
Cabannes-Hamy A et al. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. Haematologica 2022;107(9):2072-80. Abstract
Chalandon Y et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 2015;125(24):3711-9. Abstract
Gökbuget N et al. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 2020;61(11):2665-73. Abstract
Jabbour E et al. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: Post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial. Lancet Haematol 2025;12(7):e529-41. Abstract
Jabbour E et al. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol 2024;99(4):586-95. Abstract
Kantarjian H et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017; 376:836-47. Abstract
Li Y et al. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci Adv 2022;8(50):eadd6403. Abstract
Litzow MR et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med 2024;391(4):320-33. Abstract
Paietta E et al. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood 2021;138(11):948-58. Abstract
Short NJ et al. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. J Hematol Oncol 2025;18(1):55. Abstract
Short NJ et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 2022;6(13):4006-14. Abstract
Wang Y et al. Updated results from the phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia. ASH 2025;Abstract 647.
Yoshimura S et al. Impact of age on pharmacogenomics and treatment outcomes of B-cell acute lymphoblastic leukemia. J Clin Oncol 2024;42(29):3478-90. Abstract